Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia

Fig. 5

Impaired capacity of CD106+/CD106 BM-MSCs from aplastic anemia (AA) patients and controls to support and maintain hematopoiesis and angiogenesis in xenotransplanted NOD/SCID mice. A,B The percentage of human CD45+ cells in mice transplanted with unsorted mesenchymal stem cells (UMSCs), CD106+ MSCs, or CD106 MSCs from healthy controls (n = 5) (Aa, Ab, Ac, and B) and AA patients (n = 5) (Ad, Ae, Af, and B). C The survival of mice cotransplanted with UCB CD34+ cells and unsorted MSCs from healthy controls was superior compared with that of mice cotransplanted with same cells from AA patients (a). The survival of mice cotransplanted with UCB CD34+ cells and CD106+ MSCs was superior compared with that of mice cotransplanted with CD106 MSCs from healthy controls (b) or AA patients (c). The survival of mice cotransplanted with UCB CD34+ cells and CD106+ MSCs from healthy controls was superior compared with that of mice cotransplanted with the same cells from AA patients (d). Data are represented as the mean ± standard error. **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page